Nicotinamide Riboside Supplementation Restores Myocardial Nicotinamide Adenine Dinucleotide Levels, Improves Survival, and Promotes Protective Environment Post Myocardial Infarction.

Cardiac remodeling Cytokine Energy metabolism Inflammation

Journal

Cardiovascular drugs and therapy
ISSN: 1573-7241
Titre abrégé: Cardiovasc Drugs Ther
Pays: United States
ID NLM: 8712220

Informations de publication

Date de publication:
24 Nov 2023
Historique:
accepted: 10 11 2023
medline: 24 11 2023
pubmed: 24 11 2023
entrez: 24 11 2023
Statut: aheadofprint

Résumé

Myocardial infarction (MI) is a major cause of death. Nicotinamide adenine dinucleotide (NAD MI was induced by LAD ligation in 2-3-month-old male mice. NR was administered daily (1 µmole/g body weight) over 7 days. RT-PCR showed a 60-fold increase in nicotinamide riboside kinase 2 expression 4 days post-MI with a 60% drop in myocardial NAD Our data show that nicotinamide riboside could be useful for MI management.

Identifiants

DOI: 10.1007/s10557-023-07525-1 PMID: 37999834
pubmed: 37999834
doi: 10.1007/s10557-023-07525-1
pii: 10.1007/s10557-023-07525-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Faculty of Medicine, American University of Beirut
ID : MPP - 320145
Organisme : Faculty of Medicine, American University of Beirut
ID : URB - 103949 MPP - 320095
Organisme : Faculty of Medicine, American University of Beirut
ID : MPP - 320095
Organisme : Centre National de la Recherche Scientifique
ID : 103507/103487/103941/103944
Organisme : Institut pour la Recherche sur la Moelle épinière et l'Encéphale
ID : ANR-17-CE17-0015-01
Organisme : Fondation de France
ID : 00075811

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.  https://doi.org/10.1016/S0140-6736(17)32154-2 .
Cohen M, Gensini GF, Maritz F, et al. Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial. Circulation. 2003;108(16 Suppl 1):III14-21.  https://doi.org/10.1161/01.CIR.0000091832.74006.1C .
pubmed: 14605015
Eagle KA, Goodman SG, Avezum A, et al. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet. 2002;359(9304):373–7.  https://doi.org/10.1016/S0140-6736(02)07595-5 .
doi: 10.1016/S0140-6736(02)07595-5 pubmed: 11844506
Srivastava S. Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders. Clin Transl Med. 2016;5(1):25.  https://doi.org/10.1186/s40169-016-0104-7 .
doi: 10.1186/s40169-016-0104-7 pubmed: 27465020 pmcid: 4963347
Winnik S, Auwerx J, Sinclair DA, Matter CM. Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J. 2015;36(48):3404–12.  https://doi.org/10.1093/eurheartj/ehv290 .
doi: 10.1093/eurheartj/ehv290 pubmed: 26112889 pmcid: 4685177
Pacher P, Szabo C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev. 2007;25(3):235–60.  https://doi.org/10.1111/j.1527-3466.2007.00018.x .
doi: 10.1111/j.1527-3466.2007.00018.x pubmed: 17919258 pmcid: 2225457
Pillai VB, Sundaresan NR, Kim G, et al. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J Biol Chem. 2010;285(5):3133–44.  https://doi.org/10.1074/jbc.M109.077271 .
doi: 10.1074/jbc.M109.077271 pubmed: 19940131
Zhang Y, Wang B, Fu X, et al. Exogenous NAD(+) administration significantly protects against myocardial ischemia/reperfusion injury in rat model. Am J Transl Res. 2016;8(8):3342–50.
pubmed: 27648125 pmcid: 5009387
Trammell SA, Yu L, Redpath P, Migaud ME, Brenner C. Nicotinamide riboside is a major NAD+ precursor vitamin in cow milk. J Nutr. 2016;146(5):957–63.  https://doi.org/10.3945/jn.116.230078 .
doi: 10.3945/jn.116.230078 pubmed: 27052539 pmcid: 6879052
Trammell SA, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948.  https://doi.org/10.1038/ncomms12948 .
doi: 10.1038/ncomms12948 pubmed: 27721479 pmcid: 5062546
Hsu CP, Oka S, Shao D, Hariharan N, Sadoshima J. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ Res. 2009;105(5):481–91.  https://doi.org/10.1161/CIRCRESAHA.109.203703 .
doi: 10.1161/CIRCRESAHA.109.203703 pubmed: 19661458 pmcid: 2765790
Diguet N, Trammell SAJ, Tannous C, et al. Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy. Circulation. 2018;137(21):2256–73.  https://doi.org/10.1161/CIRCULATIONAHA.116.026099 .
doi: 10.1161/CIRCULATIONAHA.116.026099 pubmed: 29217642
Ghali R, Habeichi N, Kaplan A et al. IL-33 induces type-2-cytokine phenotype but exacerbates cardiac remodeling post-myocardial infarction with eosinophil recruitment, worsened systolic dysfunction, and ventricular wall rupture. Clin Sci (Lond). 2020.  https://doi.org/10.1042/CS20200402 .
Nie X, Li C, Hu S, Xue F, Kang YJ, Zhang W. An appropriate loading control for western blot analysis in animal models of myocardial ischemic infarction. Biochem Biophys Rep. 2017;12:108–13.  https://doi.org/10.1016/j.bbrep.2017.09.001 .
pubmed: 28955798 pmcid: 5613232
Kuznetsov AV, Veksler V, Gellerich FN, Saks V, Margreiter R, Kunz WS. Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells. Nat Protoc. 2008;3(6):965–76.  https://doi.org/10.1038/nprot.2008.61 .
doi: 10.1038/nprot.2008.61 pubmed: 18536644
Grimbert L, Sanz MN, Gressette M, et al. Spatiotemporal AMPKalpha2 deletion in mice induces cardiac dysfunction, fibrosis and cardiolipin remodeling associated with mitochondrial dysfunction in males only. Biol Sex Differ. 2021;12(1):52.  https://doi.org/10.1186/s13293-021-00394-z .
doi: 10.1186/s13293-021-00394-z pubmed: 34535195 pmcid: 8447586
Xie N, Zhang L, Gao W, et al. NAD(+) metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther. 2020;5(1):227.  https://doi.org/10.1038/s41392-020-00311-7 .
doi: 10.1038/s41392-020-00311-7 pubmed: 33028824 pmcid: 7539288
Larsen S, Nielsen J, Hansen CN, et al. Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects. J Physiol. 2012;590(14):3349–60.  https://doi.org/10.1113/jphysiol.2012.230185 .
doi: 10.1113/jphysiol.2012.230185 pubmed: 22586215 pmcid: 3459047
Klimova N, Fearnow A, Kristian T. Role of NAD(+)-modulated mitochondrial free radical generation in mechanisms of acute brain injury. Brain Sci. 2020;10(7).  https://doi.org/10.3390/brainsci10070449 .
Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD(+) metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119–41.  https://doi.org/10.1038/s41580-020-00313-x .
doi: 10.1038/s41580-020-00313-x pubmed: 33353981
Canto C, Menzies KJ, Auwerx J. NAD(+) Metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 2015;22(1):31–53.  https://doi.org/10.1016/j.cmet.2015.05.023 .
doi: 10.1016/j.cmet.2015.05.023 pubmed: 26118927 pmcid: 4487780
Tannous C, Booz GW, Altara R, et al. Nicotinamide adenine dinucleotide: Biosynthesis, consumption and therapeutic role in cardiac diseases. Acta Physiol (Oxf). 2021;231(3):e13551.  https://doi.org/10.1111/apha.13551 .
doi: 10.1111/apha.13551 pubmed: 32853469
Cameron AM, Castoldi A, Sanin DE, et al. Inflammatory macrophage dependence on NAD(+) salvage is a consequence of reactive oxygen species-mediated DNA damage. Nat Immunol. 2019;20(4):420–32.  https://doi.org/10.1038/s41590-019-0336-y .
doi: 10.1038/s41590-019-0336-y pubmed: 30858618
Tannous C, Deloux R, Karoui A et al. NMRK2 gene is upregulated in dilated cardiomyopathy and required for cardiac function and NAD levels during aging. Int J Mol Sci. 2021;22(7).  https://doi.org/10.3390/ijms22073534 .
Ma S, Feng J, Lin X, et al. Nicotinamide riboside alleviates cardiac dysfunction and remodeling in pressure overload cardiac hypertrophy. Oxid Med Cell Longev. 2021;2021:5546867.  https://doi.org/10.1155/2021/5546867 .
doi: 10.1155/2021/5546867 pubmed: 34567409 pmcid: 8463245
Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286.  https://doi.org/10.1038/s41467-018-03421-7 .
doi: 10.1038/s41467-018-03421-7 pubmed: 29599478 pmcid: 5876407
Rajamohan SB, Pillai VB, Gupta M, et al. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol Cell Biol. 2009;29(15):4116–29.  https://doi.org/10.1128/MCB.00121-09 .
doi: 10.1128/MCB.00121-09 pubmed: 19470756 pmcid: 2715814
Kuznetsov AV, Javadov S, Margreiter R, Grimm M, Hagenbuchner J, Ausserlechner MJ. The role of mitochondria in the mechanisms of cardiac ischemia-reperfusion injury. Antioxidants (Basel). 2019;8(10).  https://doi.org/10.3390/antiox8100454 .
Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 2016;365(3):563–81.  https://doi.org/10.1007/s00441-016-2431-9 .
doi: 10.1007/s00441-016-2431-9 pubmed: 27324127 pmcid: 5010608
Zhou B, Wang DD, Qiu Y, et al. Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure. J Clin Invest. 2020;130(11):6054–63.  https://doi.org/10.1172/JCI138538 .
doi: 10.1172/JCI138538 pubmed: 32790648 pmcid: 7598081
Engelbertsen D, Andersson L, Ljungcrantz I, et al. T-helper 2 immunity is associated with reduced risk of myocardial infarction and stroke. Arterioscler Thromb Vasc Biol. 2013;33(3):637–44.  https://doi.org/10.1161/ATVBAHA.112.300871 .
doi: 10.1161/ATVBAHA.112.300871 pubmed: 23307873

Auteurs

Cynthia Tannous (C)

Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut Medical Center, Riad El-Solh, Beirut, 1107 2020, Lebanon.
Department of Signaling and Cardiovascular Pathophysiology, UMR-S 1180, Université Paris-Saclay, Inserm, 17 avenue des Sciences, 91 400, Orsay, France.
The Cardiovascular, Renal and Metabolic Diseases Research Center of Excellence, American University of Beirut Medical Center, Riad El-Solh, Beirut, Lebanon.

Rana Ghali (R)

Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut Medical Center, Riad El-Solh, Beirut, 1107 2020, Lebanon.
The Cardiovascular, Renal and Metabolic Diseases Research Center of Excellence, American University of Beirut Medical Center, Riad El-Solh, Beirut, Lebanon.

Ahmed Karoui (A)

Department of Signaling and Cardiovascular Pathophysiology, UMR-S 1180, Université Paris-Saclay, Inserm, 17 avenue des Sciences, 91 400, Orsay, France.

Nada J Habeichi (NJ)

Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut Medical Center, Riad El-Solh, Beirut, 1107 2020, Lebanon.
Department of Signaling and Cardiovascular Pathophysiology, UMR-S 1180, Université Paris-Saclay, Inserm, 17 avenue des Sciences, 91 400, Orsay, France.
The Cardiovascular, Renal and Metabolic Diseases Research Center of Excellence, American University of Beirut Medical Center, Riad El-Solh, Beirut, Lebanon.
MatriceLab Innove Laboratory, Immeuble Les Gemeaux, 2 Rue Antoine Etex, 94000 Creteil, France.

Ghadir Amin (G)

Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut Medical Center, Riad El-Solh, Beirut, 1107 2020, Lebanon.
The Cardiovascular, Renal and Metabolic Diseases Research Center of Excellence, American University of Beirut Medical Center, Riad El-Solh, Beirut, Lebanon.
Department of Pharmacology and Toxicology, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.

George W Booz (GW)

Department of Pharmacology and Toxicology, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.

Mathias Mericskay (M)

Department of Signaling and Cardiovascular Pathophysiology, UMR-S 1180, Université Paris-Saclay, Inserm, 17 avenue des Sciences, 91 400, Orsay, France. mathias.mericskay@inserm.fr.

Marwan Refaat (M)

Department of Cardiovascular Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

Fouad A Zouein (FA)

Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut Medical Center, Riad El-Solh, Beirut, 1107 2020, Lebanon. fouadzouein@outlook.com.
Department of Signaling and Cardiovascular Pathophysiology, UMR-S 1180, Université Paris-Saclay, Inserm, 17 avenue des Sciences, 91 400, Orsay, France. fouadzouein@outlook.com.
The Cardiovascular, Renal and Metabolic Diseases Research Center of Excellence, American University of Beirut Medical Center, Riad El-Solh, Beirut, Lebanon. fouadzouein@outlook.com.
Department of Pharmacology and Toxicology, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA. fouadzouein@outlook.com.
ORCID: 0000-0003-4451-804X

Classifications MeSH